No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
www.lupin.comNo one on the platform currently holds LUPIN.NS.
No tracked institution reports a position in LUPIN.NS as of their last filing.
No one on the platform has traded LUPIN.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 22.9% | — | — | — | ||
| Rev. Growth % | 23.1% | 13.0% | ||||
| Profit Margin % | 19.1% | 7.3% | 6.3% | |||
| Free Cash Flow Margin % | 18.4% | 7.4% | 6.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $303.0B | +11.7% | $95.31 | $89.52–$102.77 | — | 32 |
| 2028 | $324.4B | +7.1% | $102.37 | $73.30–$117.87 | — | 33 |
| 2029 | $351.8B | +8.5% | $118.88 | $107.91–$128.10 | — | 15 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $29.19 | $31.00 | +6.2% |
| 2026-05-06 | $26.76 | $34.75 | +29.9% |
| 2026-02-11 | $27.57 | $33.67 | +22.1% |
| 2025-11-06 | $26.08 | $32.32 | +23.9% |
| 2025-08-05 | $23.58 | $26.70 | +13.2% |
| 2025-05-14 | $16.52 | $17.00 | +2.9% |
| 2025-02-11 | $17.12 | $18.90 | +10.4% |
| 2024-11-07 | $16.25 | $18.70 | +15.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| LUPIN.NSLupin Limited | $2095.00 | +0.83% | $957.9B | — |
| ALKEM.BOAlkem Laboratories Limited | $5089.50 | -0.41% | $607.6B | — |
| ALKEM.NSAlkem Laboratories Limited | $5089.50 | -0.94% | $608.5B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1675.45 | +0.39% | $963.7B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1679.80 |
| +0.68% |
| $966.5B |
| — |
| DRREDDY.BODr. Reddy's Laboratories Limited | $1161.00 | +1.77% | $975.5B | — |
| DRREDDY.NSDr. Reddy's Laboratories Limited | $1165.50 | +1.97% | $970.9B | — |
Source: Financial Modeling Prep · peers by sector/industry